PharmaCyte Biotech (PMCB) Intangibles (2013 - 2026)

PharmaCyte Biotech (PMCB) has reported Intangibles for 14 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Intangibles changed 0.0% year-over-year to $1.5 million; the TTM figure through Jan 2026 stood at $1.5 million (changed 0.0% YoY), while the FY2025 annual figure was $1.5 million, changed 0.0% from the prior year.
• Intangibles was little changed at $1.5 million in Q1 2026 per PMCB's latest filing, from $1.5 million in the prior quarter.
• Across five years, Intangibles topped out at $3.5 million in Q1 2022 and bottomed at $1.5 million in Q2 2024.
• Historically, Intangibles has averaged $2.6 million across 5 years, with a median of $3.5 million in 2022.
• Annual changes were most pronounced in 2022 — Intangibles changed 0.0% — and 2024, when it tumbled 56.35%.
• PharmaCyte Biotech's Intangibles stood at $3.5 million in 2022, then changed by 0.0% to $3.5 million in 2023, then sank by 56.35% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
• Business Quant data shows PMCB's Intangibles at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.